Purpose | Dosage Range | Frequency | Administration |
---|---|---|---|
Sleep Enhancement | 50-200 mcg | Once daily | Subcutaneous injection |
Research | 25-1000 mcg | As per protocol | Subcutaneous/Intravenous |
Stress Reduction | 100-200 mcg | Once daily | Subcutaneous injection |
2. What is DSIP?
Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
Molecular formula: C35H48N10O13
Molecular weight: 848.8 g/mol
First isolated from rabbit brain in 1977
Found in various tissues, including brain, heart, and kidneys
Known for its potential sleep-inducing and stress-reducing properties
Interacts with GABA and opioid systems in the brain
Modulates neurotransmitter release, including norepinephrine and dopamine
Influences the hypothalamic-pituitary-adrenal (HPA) axis
May affect circadian rhythms and sleep-wake cycles
Potential antioxidant and neuroprotective properties
Influences pain perception pathways
Modulates stress response systems
May enhance slow-wave sleep (deep sleep)
Potential treatment for insomnia and sleep disorders
Could help regulate sleep-wake cycles
Potential anxiolytic (anti-anxiety) effects
May help in stress management and adaptation
Possible analgesic properties
Potential adjunct therapy in chronic pain conditions
Influences various hormone levels, including LH, ACTH, and prolactin
Potential applications in endocrine disorders
Possible protective effects against oxidative stress in neurons
Potential applications in neurodegenerative diseases
May help in managing withdrawal symptoms
Potential role in addiction treatment protocols
Typical dose: 50-200 mcg
Administered subcutaneously once daily, preferably before bedtime
Dose range: 25-1000 mcg
Frequency depends on specific research protocol
Typical dose: 100-200 mcg
Administered subcutaneously once daily
Reconstitute lyophilized DSIP with bacteriostatic water
Use sterile injection materials
Calculate dosage based on concentration (e.g., 1 mg/ml)
Draw correct amount into insulin syringe
Administer via subcutaneous injection
Most common method for research and general use
Inject into fatty tissue of abdomen or thigh
Used in some research protocols
Not typically recommended for non-clinical settings
Potential synergistic effects on sleep quality
May enhance overall sleep-inducing properties
Possible interaction, use with caution
May potentiate sedative effects
Mild drowsiness
Transient changes in appetite
Potential changes in hormone levels
Not approved by the FDA for human use
Legal status varies by country and jurisdiction
Often restricted to research or medical use
In the US, it's legal to possess for research purposes but not for human consumption
Store lyophilized powder at -20°C (-4°F)
Once reconstituted, store in refrigerator (2-8°C or 36-46°F)
Use within 30 days after reconstitution
Protect from light and excessive heat
Always use sterile techniques when handling
Effects may be noticeable within 30-60 minutes of administration, but individual responses can vary.
Long-term safety and efficacy data are limited. Consult a healthcare professional for extended use.
Some studies suggest potential cognitive benefits, but more research is needed to confirm these effects.
DSIP may offer a more natural approach to sleep regulation, potentially with fewer side effects, but direct comparisons are limited.
DSIP shows promise as a potential sleep-enhancing and stress-reducing peptide with a range of possible applications in neurology and endocrinology. The typical dosage range of 50-200 mcg administered once daily appears effective for most research applications. Its unique properties in modulating sleep, stress response, and potentially pain perception make it an intriguing subject for further study.However, its use should be approached cautiously due to limited long-term human safety data and varying legal status worldwide. As with any experimental compound, thorough research and professional consultation are essential before use. The potential of DSIP in sleep disorders, stress management, and neurological conditions warrants further investigation, particularly in larger, long-term human trials.
Monnier M, et al. (1977). The delta sleep-inducing peptide (DSIP). Comparative properties of the original and synthetic nonapeptide. Experientia, 33(4), 548-552.
Graf MV, Kastin AJ. (1986). Delta-sleep-inducing peptide (DSIP): an update. Peptides, 7(6), 1165-1187.
Yehuda S, Carasso RL. (1988). DSIP--a tool for investigating the sleep onset mechanism: a review. International Journal of Neuroscience, 38(3-4), 345-353.
Pollard BJ, Pomfrett CJ. (2001). Delta sleep-inducing peptide. European Journal of Anaesthesiology, 18(6), 419-422.
Shandra OO, et al. (2016). Delta Sleep-Inducing Peptide and Its Analogs as Neuroprotectors in Neurodegenerative Diseases. CNS & Neurological Disorders - Drug Targets, 15(8), 973-977.
Disclaimer
Peptideresearcher.com contains information about products intended for research and laboratory use only, unless otherwise explicitly stated. All content is for educational purposes and is not meant to substitute for professional medical advice. Peptideresearcher.com strives to ensure that all information presented is accurate and complies with national and international standards, but it is not guaranteed. The content provided is not intended to diagnose, treat, cure, or prevent any disease or condition.
Peptideresearcher.com does not offer medical diagnoses or prescriptions. Any product information shared is solely for research purposes and should be used by qualified professionals only. We advise all users to consult with a healthcare professional before using any peptides, supplements, or medications mentioned on this site. All opinions expressed are those of the individual authors and may not reflect the opinions of Peptideresearcher.com.
Copyright 2024 - Peptide Researcher
Your access to Peptideresearcher.com is subject to our Terms of Use